It is considered potentially harmful to administer imipenem–cilastatin to patients with IgE-mediated hypersensitivity to penicillins
1 because of a 47.4 percent rate of cross-reactivity (9 of 19 subjects) found in a single study
2 on the basis of positive skin tests involving imipenem reagents.